Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease
- PMID: 21997546
- DOI: 10.1136/gutjnl-2011-300798
Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease
Abstract
Objective: Approximately 30% of patients with gastro-oesophageal reflux disease (GORD) do not achieve adequate symptom control with proton pump inhibitors (PPIs). The aim of this study was to determine whether any symptom profile or reflux pattern was associated with refractoriness to PPI therapy.
Design: Patients with typical GORD symptoms (heartburn and/or regurgitation) were included and had 24 h pH-impedance monitoring off therapy. Patients were considered to be responders if they had fewer than 2 days of mild symptoms per week while receiving a standard or double dose of PPI treatment for at least 4 weeks. Both clinical and reflux parameters were taken into account for multivariate analysis (logistic regression).
Results: One hundred patients were included (median age 50 years, 42 male), 43 responders and 57 non-responders. Overall, multivariate analysis showed that the factors associated with the absence of response were absence of oesophagitis (p=0.050), body mass index (BMI) ≤25 kg/m(2) (p=0.002) and functional dyspepsia (FD) (p=0.001). In patients who reported symptoms during the recording (n=85), the factors associated with PPI failure were BMI ≤25 kg/m(2) (p=0.004), FD (p=0.009) and irritable bowel syndrome (p=0.045). In patients with documented GORD (n=67), the factors associated with PPI failure were absence of oesophagitis (p=0.040), FD (p=0.003), irritable bowel syndrome (p=0.012) and BMI ≤25 kg/m(2) (p=0.029).
Conclusion: No reflux pattern demonstrated by 24 h pH-impedance monitoring is associated with response to PPIs in patients with GORD symptoms. In contrast, absence of oesophagitis, presence of functional digestive disorders and BMI ≤25 kg/m(2) are strongly associated with PPI failure.
Comment in
-
Studies on factors predicting GORD response to proton-pump inhibitors: NERD subpopulations need to be analysed separately.Gut. 2012 Sep;61(9):1368-9. doi: 10.1136/gutjnl-2011-301624. Epub 2011 Dec 9. Gut. 2012. PMID: 22157332 No abstract available.
Similar articles
-
pH-Impedance Findings and proton pump inhibitors-responsiveness in patients with typical gastroesophageal reflux disease symptoms in a large single-center Italian series.J Clin Gastroenterol. 2014 Aug;48(7):613-9. doi: 10.1097/MCG.0000000000000051. J Clin Gastroenterol. 2014. PMID: 24326754
-
Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.Neurogastroenterol Motil. 2011 Feb;23(2):155-60, e31. doi: 10.1111/j.1365-2982.2010.01627.x. Epub 2010 Nov 19. Neurogastroenterol Motil. 2011. PMID: 21087355
-
Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2012 Jun;35(11):1279-89. doi: 10.1111/j.1365-2036.2012.05085.x. Epub 2012 Apr 8. Aliment Pharmacol Ther. 2012. PMID: 22486552 Clinical Trial.
-
Management of heartburn not responding to proton pump inhibitors.Gut. 2009 Feb;58(2):295-309. doi: 10.1136/gut.2007.145581. Gut. 2009. PMID: 19136523 Review.
-
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.Gut. 2011 Nov;60(11):1473-8. doi: 10.1136/gut.2011.241307. Epub 2011 Apr 20. Gut. 2011. PMID: 21508423 Review.
Cited by
-
What is the profiles for predicting treatment responsiveness in gastroesophageal reflux disease? (Gut 2012;61:501-506).J Neurogastroenterol Motil. 2012 Jul;18(3):342-4. doi: 10.5056/jnm.2012.18.3.342. Epub 2012 Jul 10. J Neurogastroenterol Motil. 2012. PMID: 22837886 Free PMC article. No abstract available.
-
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.Meta Gene. 2016 Jun 18;9:159-64. doi: 10.1016/j.mgene.2016.06.004. eCollection 2016 Sep. Meta Gene. 2016. PMID: 27419077 Free PMC article.
-
Symptom analysis improves GERD diagnosis and may be helpful to define a successful surgical approach.Surg Endosc. 2014 Feb;28(2):698-9. doi: 10.1007/s00464-013-3174-2. Epub 2013 Aug 31. Surg Endosc. 2014. PMID: 23996339 No abstract available.
-
The Rome IV versus Rome III criteria for heartburn diagnosis: A comparative study.United European Gastroenterol J. 2018 Apr;6(3):358-366. doi: 10.1177/2050640617735084. Epub 2017 Sep 27. United European Gastroenterol J. 2018. PMID: 29774149 Free PMC article.
-
Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters.Am J Gastroenterol. 2014 Jun;109(6):836-44. doi: 10.1038/ajg.2014.63. Epub 2014 Apr 15. Am J Gastroenterol. 2014. PMID: 24732868 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical